The conjunction of "hard genetics" research centers, with well established biomedical and bioethics research groups, and the exceptional possibility to hold the 6th annual meeting of the African
There is a need to determine the differences in allele frequencies in African subpopulations for genes involved in specific medication as well as the need for case-control studies for adverse drug reactions in patients in Africa. The ultimate goal of such phamacogenomics studies is to reduce medication costs (use medications only in patients who will benefit) and improved medication safety (i.e., avoid serious adverse drug reactions, improved understanding of population differences in susceptibility to ADRs, prevention of disability in communities with less resources).
Presenting a very interactive clinical approach to dysmorphology, Dr Armand Bottani (Geneva University Hospital, Switzerland) showed that trying to reach a definite diagnosis in patients with peculiar physical traits and/or mental retardation is a challenging task in clinical genetics, but a prerequisite one for an adequate genetic counseling. Much information leading to the delineation of a potentially known condition or syndrome can be gathered from a systematic clinical examination, paying particular attention to some key dysmorphic elements. He illustrated some of them and gave an overview on how to proceed as a clinician when facing such patients. In the context, could molecular cytogenetic replace classical The sub-Saharan African Region needs significant capacity building in the area of basic research in general and genetics (especially Human Genetics) in particular [4] . In that respect, the existence and current activities of the AfSHG and its impact at the national levels in Africa, is a major development for the continent and an initiative that needs further encouragement from the international community.
